← Back to headlines
Regeneron's Libtayo combo faces trial setback against Merck's Keytruda
Regeneron's Libtayo combination therapy has encountered a late-stage trial setback in its competition against Merck's Keytruda.
16 May, 12:55 — 16 May, 12:55
Sources
Showing 1 of 1 sources
